Article

Optimization of a sensitive and reliable UPLC-MS/MS method to simultaneously quantify almonertinib and HAS-719 and its application to study the interaction with nicardipine

2024-03-27

Abstract excerpt

Almonertinib, a novel third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, was selected by the Chinese Society of Clinical Oncology as a first-line therapy for EGFR T790M mutated non-small cell lung cancer in 2021. Almonertinib is primarily metabolized by CYP3A4, so it could interact with a variety of drugs metabolized by CYP3A4, leading to the changes of systemic exposure. For the p...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 92b8a141-57c2-5102-862b-81ec416119be
DOI: 10.21203/rs.3.rs-4116048/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Optimization of a sensitive and reliable UPLC-MS/MS method to simultaneously quantify almonertinib and HAS-719 and its application to study the interaction with nicardipineDOI 10.21203/rs.3.rs-4116048/v1Read

Effects of voriconazole and fluconazole on the pharmacokinetics of almonertinib in rats by UPLC-MS/MS.Semantic proximity Read

The inhibitory effect of isavuconazole on almonertinib metabolism and its underlying mechanismSemantic proximity Read

[A review: drug-drug interactions of epithelial growth factor receptor-tyrosine kinase inhibitors].Semantic proximity Read

Effect of Food Intake on Pharmacokinetics of Oral Almonertinib: A Randomized Crossover Trial in Healthy Chinese Participants.Semantic proximity Read

Therapeutic Drug Monitoring of Sorafenib and Lenvatinib in Hepatocellular Carcinoma Patients – A Key to Personalised PharmacotherapySemantic proximity Read

Development and validation of an LC-MS/MS method for simultaneous determination of SH-1028, an irreversible third-generation EGFR TKI, and two of its metabolites in human plasma: application in clinical pharmacokinetics.Semantic proximity Read

Evaluation of the Effect of Ritlecitinib on the Pharmacokinetics of Caffeine in Healthy ParticipantsSemantic proximity Read

Simultaneous quantitative detection of afatinib, erlotinib, gefitinib, icotinib, osimertinib and their metabolites in plasma samples of patients with non-small cell lung cancer using liquid chromatography-tandem mass spectrometry.Semantic proximity Read

Development and validation of a new liquid chromatography-tandem mass spectrometry assay for the simultaneous quantification of afatinib, dacomitinib, osimertinib, and the active metabolites of osimertinib in human serum.Semantic proximity Read

Drug-Drug Interaction Potential of SH-1028, a Third-generation EGFR-TKI: In Vitro and Clinical TrialsSemantic proximity Read

Determining plasma and cerebrospinal fluid concentrations of EGFR-TKI in lung cancer patients.Semantic proximity Read